Table 2.
eMERGE3 sites listed with total number of participants, number of participants with P/LP variants, and number of participants with disclosed P/LP variants
| Institution | Total Number of Participants | Number of Participants with P/LP Variants | Number of Participants with Returned P/LP |
|---|---|---|---|
| CCHMC prospective adolescent | 160 | 6 (3.8%) | 5 (83.3%) |
| CCHMC biobank | 2840 | 91 (3.2%) | 19 (20.9%) |
| CHOP | 2990 | 101 (3.4%) | 24 (23.8%) |
| Columbia IMAgene | 341 | 30 (8.8%) | 28 (93.3%) |
| Columbia- prospective | 1120 | 65 (5.8%) | 51 (78.5%) |
| Columbia -retrospective | 1135 | 73 (6.4%) | 18 (24.7%) |
| Geisinger | 2500 | 263 (10.5%) | 244 (92.8%) |
| KPWA/UW | 2500 | 96 (3.8%) | 58 (60.4%) |
| Mayo - Rochester | 2535 | 121 (4.8%) | 118 (97.5%) |
| Mayo - Arizona | 500 | 10 (2.0%) | 9 (90.0%) |
| Meharry | 500 | 19 (3.8%) | 14 (73.7%) |
| Northwestern | 3000 | 279 (9.3%) | 255 (88.5%) |
| Partners Healthcare | 2500 | 65 (2.6%) | 25 (35.5%) |
| VUMC | 2454 | 225(9.1%) | 209 (92.9%) |
| Total | 25,084 | 1444 (5.7%) | 1077 (74.6%) |
CCHMC, CU and MC have multiple listings representing different cohorts.
CCHMC, Cincinnati Children’s Hospital and Medical Center; CHOP, Children’s Hospital of Philadelphia; eMERGE3, Electronic Medical Records and Genomics Phase III; KPWA, Kaiser Permanente of Washington; LP, likely pathogenic; MC, Mayo Clinic; P, pathogenic; UW, University of Washington; VUMC, Vanderbilt University Medical Center.